The impact of hospital-acquired infections on the patient-level reimbursement-cost relationship in a DRG-based hospital payment system
Tóm tắt
Hospital-acquired infections (HAIs) are a common complication in inpatient care. We investigate the incentives to prevent HAIs under the German DRG-based reimbursement system. We analyze the relationship between resource use and reimbursements for HAI in 188,731 patient records from the University Medical Center Freiburg (2011–2014), comparing cases to appropriate non-HAI controls. Resource use is approximated using national standardized costing system data. Reimbursements are the actual payments to hospitals under the G-DRG system. Timing of HAI exposure, cost-clustering within main diagnoses and risk-adjustment are considered. The reimbursement-cost difference of HAI patients is negative (approximately − €4000). While controls on average also have a negative reimbursement-cost difference (approximately − €2000), HAI significantly increase this difference after controlling for confounding and timing of infection (− 1500, p < 0.01). HAIs caused by vancomycin-resistant Enterococci have the most unfavorable reimbursement-cost difference (− €10,800), significantly higher (− €9100, p < 0.05) than controls. Among infection types, pneumonia is associated with highest losses (− €8400 and − €5700 compared with controls, p < 0.05), while cost-reimbursement relationship for Clostridium difficile-associated diarrhea is comparatively balanced (− €3200 and − €500 compared to controls, p = 0.198). From the hospital administration’s perspective, it is not the additional costs of HAIs, but rather the cost-reimbursement relationship which guides decisions. Costs exceeding reimbursements for HAI may increase infection prevention and control efforts and can be used to show their cost-effectiveness from the hospital perspective.
Tài liệu tham khảo
Barnett, A. G., Beyersmann, J., Allignol, A., Rosenthal, V. D., Graves, N., & Wolkewitz, M. (2011). The time-dependent bias and its effect on extra length of stay due to nosocomial infection. Value in Health,14(2), 381–386.
Braun, J.-P., Bause, H., Bloos, F., Geldner, G., Kastrup, M., Kuhlen, R., et al. (2010). Peer reviewing critical care: A pragmatic approach to quality management. GMS German Medical Science,8, Doc23.
Chaberny, I. F., Sohr, D., Rüden, H., & Gastmeier, P. (2007). Development of a surveillance system for methicillin-resistant Staphylococcus aureus in German hospitals. Infection Control and Hospital Epidemiology,28(04), 446–452.
Demaerschalk, B. M., & Durocher, D. L. (2007). How diagnosis-related group 559 will change the US Medicare cost reimbursement ratio for stroke centers. Stroke,38(4), 1309–1312.
Gastmeier, P., Weitzel-Kage, D., Behnke, M., & Eckmanns, T. (2009). Surveillance of Clostridium difficile-associated diarrhoea with the German nosocomial infection surveillance system KISS (CDAD-KISS). International Journal of Antimicrobial Agents,33, S19–S23.
Gutmann, A., Kaier, K., Sorg, S., von zur Mühlen, C., Siepe, M., Moser, M., et al. (2015). Analysis of the additional costs of clinical complications in patients undergoing transcatheter aortic valve replacement in the German Health Care System. International Journal of Cardiology,179, 231–237. https://doi.org/10.1016/j.ijcard.2014.11.095.
Heinz, J., Fiori, W., Heusser, P., & Ostermann, T. (2013). Cost analysis of integrative inpatient treatment based on DRG data: The example of anthroposophic medicine. Evidence-Based Complementary and Alternative Medicine. https://doi.org/10.1155/2013/748932.
Heister, T., Hagist, C., & Kaier, K. (2017a). Resistance elasticity of antibiotic demand in intensive care. Health Economics,26(7), 892–909.
Heister, T., Kaier, K., & Wolkewitz, M. (2017b). Estimating the burden of nosocomial infections: Time dependency and cost clustering should be taken into account. American Journal of Infection Control,45(1), 94–95.
Hübner, C., & Flessa, S. (2016). Reimbursement for hospital-acquired infections with multidrug resistant organisms in German DRG system. Economics & Sociology,9(3), 111.
Judd, W. R., Stephens, D. M., & Kennedy, C. A. (2014). Clinical and economic impact of a quality improvement initiative to enhance early recognition and treatment of sepsis. Annals of Pharmacotherapy,48(10), 1269–1275. https://doi.org/10.1177/1060028014541792.
Kaier, K. (2012). Economic implications of the dynamic relationship between antibiotic use and hospital-acquired infections. Value in Health,15(1), 87–93.
Kaier, K., Hagist, C., Frank, U., Conrad, A., & Meyer, E. (2009). Two time-series analyses of the impact of antibiotic consumption and alcohol-based hand disinfection on the incidences of nosocomial methicillin-resistant Staphylococcus aureus infection and Clostridium difficile infection. Infection Control & Hospital Epidemiology,30(4), 346–353.
Kristensen, S. R. (2017). Financial penalties for performance in health care. Health Economics,26(2), 143–148.
Lee, G. M., Kleinman, K., Soumerai, S. B., Tse, A., Cole, D., Fridkin, S. K., et al. (2012). Effect of nonpayment for preventable infections in US hospitals. New England Journal of Medicine,367(15), 1428–1437.
Magill, S. S., Edwards, J. R., Bamberg, W., Beldavs, Z. G., Dumyati, G., Kainer, M. A., et al. (2014). Multistate point-prevalence survey of health care-associated infections. New England Journal of Medicine,370(13), 1198–1208. https://doi.org/10.1056/NEJMoa1306801.
Maragakis, L. L., Perencevich, E. N., & Cosgrove, S. E. (2008). Clinical and economic burden of antimicrobial resistance. Expert Review of Anti-Infective Therapy,6(5), 751–763.
Mitchell, B. G., & Gardner, A. (2012). Prolongation of length of stay and Clostridium difficile infection: A review of the methods used to examine length of stay due to healthcare associated infections. Antimicrobial Resistance and Infection Control,1(1), 14. https://doi.org/10.1186/2047-2994-1-14.
Mitchell, B. G., Gardner, A., Barnett, A. G., Hiller, J. E., & Graves, N. (2014). The prolongation of length of stay because of Clostridium difficile infection. American Journal of Infection Control,42(2), 164–167. https://doi.org/10.1016/j.ajic.2013.07.006.
Noskin, G. A., Rubin, R. J., Schentag, J. J., Kluytmans, J., Hedblom, E. C., Smulders, M., et al. (2005). The burden of Staphylococcus aureus infections on hospitals in the United States: An analysis of the 2000 and 2001 Nationwide Inpatient Sample Database. Archives of Internal Medicine,165(15), 1756–1761.
Quentin, W., Geissler, A., Scheller-Kreinsen, D., & Busse, R. (2010). DRG-type hospital payment in Germany: The G-DRG system. Euro Observer,12(3), 4–6.
Reinöhl, J., Gutmann, A., Kollum, M., von zur Mühlen, C., Baumbach, H., Avlar, M., et al. (2013). Transfemoral aortic valve implantation: Bleeding events, related costs and outcomes. Journal of Thrombosis and Thrombolysis,35(4), 469–475. https://doi.org/10.1007/s11239-012-0829-0.
Resch, A., Wilke, M., & Fink, C. (2009). The cost of resistance: Incremental cost of methicillin-resistant Staphylococcus aureus (MRSA) in German hospitals. The European Journal of Health Economics,10(3), 287–297.
Schumacher, M., Allignol, A., Beyersmann, J., Binder, N., & Wolkewitz, M. (2013). Hospital-acquired infections—appropriate statistical treatment is urgently needed! International Journal of Epidemiology,42, 1502–1508.
Tabak, Y. P., Zilberberg, M. D., Johannes, R. S., Sun, X., & McDonald, L. C. (2013). Attributable burden of hospital-onset Clostridium difficile infection: A propensity score matching study. Infection Control and Hospital Epidemiology,34(06), 588–596.
Thirukumaran, C. P., Glance, L. G., Temkin-Greener, H., Rosenthal, M. B., & Li, Y. (2017). Impact of Medicare’s nonpayment program on hospital-acquired conditions. Medical Care,55(5), 447–455.
Vogl, M. (2012). Assessing DRG cost accounting with respect to resource allocation and tariff calculation: The case of Germany. Health Economics Review,2(1), 15. https://doi.org/10.1186/2191-1991-2-15.
Waters, T. M., Daniels, M. J., Bazzoli, G. J., Perencevich, E., Dunton, N., Staggs, V. S., et al. (2015). Effect of Medicare’s nonpayment for hospital-acquired conditions: Lessons for future policy. JAMA Internal Medicine,175(3), 347–354.
Wernitz, M. H., Keck, S., Swidsinski, S., Schulz, S., & Veit, S. K. (2005). Cost analysis of a hospital-wide selective screening programme for methicillin-resistant Staphylococcus aureus (MRSA) carriers in the context of diagnosis related groups (DRG) payment. Clinical Microbiology & Infection,11(6), 466–471.
Wolkewitz, M., Beyersmann, J., Gastmeier, P., & Schumacher, M. (2009). Efficient risk set sampling when a time-dependent exposure is present. Methods of Information in Medicine,48(5), 438–443.
Zimlichman, E., Henderson, D., Tamir, O., Franz, C., Song, P., Yamin, C. K., et al. (2013). Health care-associated infections: A meta-analysis of costs and financial impact on the US health care system. JAMA Internal Medicine,173(22), 2039. https://doi.org/10.1001/jamainternmed.2013.9763.